[go: up one dir, main page]

GB201615917D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB201615917D0
GB201615917D0 GBGB1615917.0A GB201615917A GB201615917D0 GB 201615917 D0 GB201615917 D0 GB 201615917D0 GB 201615917 A GB201615917 A GB 201615917A GB 201615917 D0 GB201615917 D0 GB 201615917D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1615917.0A
Other versions
GB2558191A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Priority to GB1615917.0A priority Critical patent/GB2558191A/en
Publication of GB201615917D0 publication Critical patent/GB201615917D0/en
Priority to US16/334,158 priority patent/US10888546B2/en
Priority to MYPI2019001316A priority patent/MY202069A/en
Priority to ES21183659T priority patent/ES2957459T3/en
Priority to KR1020217021521A priority patent/KR20210089273A/en
Priority to MX2019003098A priority patent/MX387723B/en
Priority to ES19199780T priority patent/ES2968212T3/en
Priority to JP2019515227A priority patent/JP6781829B2/en
Priority to CA3037092A priority patent/CA3037092C/en
Priority to CN202210090188.8A priority patent/CN114272238A/en
Priority to EP17777635.8A priority patent/EP3515432B1/en
Priority to PE2019000674A priority patent/PE20191043A1/en
Priority to ES17777635T priority patent/ES2892673T3/en
Priority to CN202210401223.3A priority patent/CN114712338A/en
Priority to KR1020197010385A priority patent/KR102277635B1/en
Priority to NZ752430A priority patent/NZ752430B2/en
Priority to AU2017328907A priority patent/AU2017328907B2/en
Priority to GEAP201715035A priority patent/GEP20217239B/en
Priority to PCT/GB2017/052761 priority patent/WO2018051130A1/en
Priority to ES19199783T priority patent/ES2968453T3/en
Priority to EP19199783.2A priority patent/EP3610871B1/en
Priority to EP21183659.8A priority patent/EP3915555B1/en
Priority to PH1/2019/500579A priority patent/PH12019500579B1/en
Priority to MX2021009476A priority patent/MX392213B/en
Priority to CN201780057068.5A priority patent/CN109789126B/en
Priority to UAA201902770A priority patent/UA123919C2/en
Priority to BR112019005133-3A priority patent/BR112019005133B1/en
Priority to EP19199780.8A priority patent/EP3607936B1/en
Priority to CN202210090190.5A priority patent/CN114515284A/en
Publication of GB2558191A publication Critical patent/GB2558191A/en
Priority to IL265360A priority patent/IL265360B2/en
Priority to MX2021009475A priority patent/MX2021009475A/en
Priority to SA519401336A priority patent/SA519401336B1/en
Priority to CONC2019/0002556A priority patent/CO2019002556A2/en
Priority to ZA2019/02053A priority patent/ZA201902053B/en
Priority to US16/582,993 priority patent/US11179366B2/en
Priority to US16/582,973 priority patent/US11103480B2/en
Priority to JP2020040655A priority patent/JP7041703B2/en
Priority to AU2020202626A priority patent/AU2020202626B2/en
Priority to US17/361,819 priority patent/US11826348B2/en
Priority to US17/361,851 priority patent/US11826349B2/en
Priority to US17/361,772 priority patent/US11642330B2/en
Priority to AU2021205045A priority patent/AU2021205045C1/en
Priority to US17/467,778 priority patent/US11690823B2/en
Priority to JP2022022292A priority patent/JP7228726B2/en
Priority to US18/489,133 priority patent/US20240050404A1/en
Priority to US18/489,150 priority patent/US20240050405A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1615917.0A 2016-09-19 2016-09-19 Pharmaceutical composition Withdrawn GB2558191A (en)

Priority Applications (46)

Application Number Priority Date Filing Date Title
GB1615917.0A GB2558191A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
US16/334,158 US10888546B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MYPI2019001316A MY202069A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ES21183659T ES2957459T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
KR1020217021521A KR20210089273A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2019003098A MX387723B (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION COMPRISING GLYCOPYRRONIUM BROMIDE, FLUTICASONE PROPIONATE AND 1,1-DIFLUOROETHANE.
ES19199780T ES2968212T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
JP2019515227A JP6781829B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CA3037092A CA3037092C (en) 2016-09-19 2017-09-18 Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CN202210090188.8A CN114272238A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
EP17777635.8A EP3515432B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
PE2019000674A PE20191043A1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION
ES17777635T ES2892673T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
CN202210401223.3A CN114712338A (en) 2016-09-19 2017-09-18 pharmaceutical composition
KR1020197010385A KR102277635B1 (en) 2016-09-19 2017-09-18 pharmaceutical composition
NZ752430A NZ752430B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
AU2017328907A AU2017328907B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
GEAP201715035A GEP20217239B (en) 2016-09-19 2017-09-18 Pharmaceutical composition
PCT/GB2017/052761 WO2018051130A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ES19199783T ES2968453T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
EP19199783.2A EP3610871B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
EP21183659.8A EP3915555B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
PH1/2019/500579A PH12019500579B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2021009476A MX392213B (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITIONS COMPRISING GLYCOPYRROLATE SALTS AND 1,1-DIFLUOROETHANE.
CN201780057068.5A CN109789126B (en) 2016-09-19 2017-09-18 pharmaceutical composition
UAA201902770A UA123919C2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
BR112019005133-3A BR112019005133B1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION, METERED-DOSE INHALER, AND METHODS FOR IMPROVING THE CHEMICAL STABILITY OF A PHARMACEUTICAL COMPOSITION, AND FOR IMPROVING THE AEROSOL DISPERSION PERFORMANCE OF A PHARMACEUTICAL COMPOSITION
EP19199780.8A EP3607936B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising glycopyrrolate
CN202210090190.5A CN114515284A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
IL265360A IL265360B2 (en) 2016-09-19 2019-03-13 Pharmaceutical composition
MX2021009475A MX2021009475A (en) 2016-09-19 2019-03-15 Pharmaceutical composition.
SA519401336A SA519401336B1 (en) 2016-09-19 2019-03-17 Pharmaceutical composition
CONC2019/0002556A CO2019002556A2 (en) 2016-09-19 2019-03-19 Pharmaceutical composition
ZA2019/02053A ZA201902053B (en) 2016-09-19 2019-04-02 Pharmaceutical composition
US16/582,993 US11179366B2 (en) 2016-09-19 2019-09-25 Pharmaceutical composition
US16/582,973 US11103480B2 (en) 2016-09-19 2019-09-25 Pharmaceutical composition
JP2020040655A JP7041703B2 (en) 2016-09-19 2020-03-10 Pharmaceutical composition
AU2020202626A AU2020202626B2 (en) 2016-09-19 2020-04-17 Pharmaceutical composition
US17/361,819 US11826348B2 (en) 2016-09-19 2021-06-29 Pharmaceutical composition
US17/361,851 US11826349B2 (en) 2016-09-19 2021-06-29 Pharmaceutical composition
US17/361,772 US11642330B2 (en) 2016-09-19 2021-06-29 Pharmaceutical composition
AU2021205045A AU2021205045C1 (en) 2016-09-19 2021-07-14 Pharmaceutical composition
US17/467,778 US11690823B2 (en) 2016-09-19 2021-09-07 Pharmaceutical composition
JP2022022292A JP7228726B2 (en) 2016-09-19 2022-02-16 Pharmaceutical composition
US18/489,133 US20240050404A1 (en) 2016-09-19 2023-10-18 Pharmaceutical composition
US18/489,150 US20240050405A1 (en) 2016-09-19 2023-10-18 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1615917.0A GB2558191A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
GB201615917D0 true GB201615917D0 (en) 2016-11-02
GB2558191A GB2558191A (en) 2018-07-11

Family

ID=57288780

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1615917.0A Withdrawn GB2558191A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Country Status (1)

Country Link
GB (1) GB2558191A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
PE20221867A1 (en) * 2020-01-28 2022-12-02 Chiesi Farm Spa PRESSURIZED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION
GB2597755A (en) * 2020-08-03 2022-02-09 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2024157282A1 (en) * 2023-01-24 2024-08-02 Cipla Limited Pharmaceutical compositions of green propellant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505717A (en) * 2011-02-17 2014-03-06 シプラ・リミテッド Pharmaceutical composition
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions

Also Published As

Publication number Publication date
GB2558191A (en) 2018-07-11

Similar Documents

Publication Publication Date Title
IL265260B (en) Pharmaceutical composition
IL265360B (en) Pharmaceutical composition
IL262654A (en) Pharmaceutical composition
IL271986B1 (en) Pharmaceutical composition
IL265349A (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
GB201521462D0 (en) Pharmaceutical composition
HUE068810T2 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
PL3646867T3 (en) Pharmaceutical composition
PL3454838T3 (en) Pharmaceutical composition
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmaceutical composition
ZA201705782B (en) Pharmaceutical compositions
PL3424500T3 (en) Pharmaceutical composition comprising famitinib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
PT3476391T (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)